Browse by category

In 2025, approximately 4.9 million British adults — almost one in ten — are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The GLP-1 and GLP-1/GIP medications liraglutide, semaglutide and tirzepatide are licensed for weight loss in the UK but only around 220,000 people will be eligible for treatment with these

A new study co-led by the Southern California Superfund Research and Training Program for PFAS Assessment, Remediation and Prevention (ShARP) Center and the University of Hawai'i has linked certain common "forever chemicals" to a higher risk of liver disease in adolescents. Perfluoroheptanoic acid (PFHpA) These synthetic compounds, known as per- and polyfluoroalkyl substances (PFAS), may as much as triple the chances that adolescents develop a liver condition called metabolic

The FDA has approved Novo Nordisk’s once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the US. The Wegovy pill can be used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off. The pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with

Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2

Bariatric patients may need closer monitoring of their prescription medications post-surgery to avoid risk of harm, according to researchers at King’s College London. Their study found that bariatric surgery patients face unique risk factors relating to overdose. This is because the surgical changes to their stomach and intestine to reduce food and nutrient absorption, can also affect how they absorb drugs. By examining data from the National Programme of Substance Use Mortal

A study by researchers at the Federal University of São Carlos (UFSCar) in Brazil, in partnership with University College London (UCL) in the United Kingdom, has concluded that the combination of abdominal fat and muscle loss increases the risk of death by 83%, compared to people without these conditions. This combination is so dangerous that it identifies an even greater problem: sarcopenic obesity. This condition is characterised by loss of muscle mass while gaining fat thr

Results from the Phase 3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of the two highest investigational doses of retatrutide, revealed retatrutide lowered weight by up to an average of 28.7% (71.2 lbs) and reduced pain by up to an average of 4.5 points (75.8%) using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score. Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecul

The first patient has been treated in Nitinotes’ US Investigational Device Exemption (IDE) EASE Clinical Trial evaluating the EndoZip Automated Suturing System for endoscopic sleeve gastroplasty (ESG). The procedure was performed at Lenox Hill Hospital | Northwell Health in New York, NY, the trial's first activated US site. The EASE Clinical Trial is a prospective, multi-centre, randomised, two-arm, blinded pivotal study designed to evaluate the safety and effectiveness of th

Corbus Pharmaceuticals has completed the single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study (CANYON-1), with completion expected in the summer of 2026. CRB-913 is an oral small molecule inverse agonist of the G-protein Coupled Receptor (GPCR) cannabinoid type-1 (CB1). This is a recognized mechanism of action for weight loss, but the first generation of experimental drugs in this cla

Transoral outlet reduction (TORe) and anastomotic reduction techniques are gaining momentum as minimally invasive alternatives to surgical revision for managing post-surgical complications such as weight regain and dumping syndrome.(1) BARS® — a novel endoscopic platform developed by Ovesco Endoscopy AG — is among the emerging technologies in this field. As clinical experience with BARS® grows, early data on weight regain management and targeted treatment approaches for enlar